It is not apparent from comparison of PFS of axitinib in this trial and of everolimus in the RECORD-1 trial that switching mechanism of action or maintaining VEGF suppression is a superior strategy in patients with renal cell carcinoma. This evidence concerns the gene VEGFA and renal cell carcinoma.